200 CDER Staff Say Goodbye To White Oak, For Now
This article was originally published in The Tan Sheet
Executive Summary
Approximately 200 employees in FDA's Center for Drug Evaluation and Research are exiled from the agency’s White Oak campus for the next few years due to overcrowding.
You may also be interested in...
CDER's Generational Shift Brings New Reviewers With Little Experience
The past two fiscal years have seen great gains in the number of new employees hired in FDA's Center for Drug Evaluation and Research, but the result is a relatively under-experienced staff: 38 percent of employees in both CDER and the Office of New Drugs have less than two years of on-the-job experience
FDA’s 5-Year Plan For User Fees Gives Equal Footing To Post- And Pre-Market
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.